Sunday, September 24

Main Hall

14:00 - 16:50

S-1

IATDMCT-JSTDM Joint Symposium:
Expansion and evolution of TDM and CT

Chairs: Loralie J. Langman, USA / Masahiro Okuda, Japan

S-1-1

Recollections: 1st CJSTDM & 1st ICTDM
Kazuhiko Tanaka (The first Congress Chair of ICTDM, Japan)

S-1-2

History of IATDMCT
Steven How-Yan Wong (The first President of IATDMCT, Wake Forest School of Medicine, USA)

S-1-3

Liaison between IATDMCT and Members
Denise Anne McKeown (IATDMCT Communication Committee, MSci, UK)

S-1-4

Overview of Clinical Toxicology
Gwendolyn Appell McMillin (University of Utah and ARUP Laboratories, USA)

S-1-5

The role of the laboratory in optimizing anti-infective therapies in critically ill patients
Pierre Wallemacq (Cliniques universitaires St Luc, Brussels, Belgium)

S-1-6

Improving clinical outcome using TDM
Teun van Gelder (Erasmus Medical Center Rotterdam, The Netherlands)

S-1-7

Expansion and Evolution of TDM and CT
Yusuke Tanigawara (15th Congress Chair, Keio University, Japan)

17:00 - 18:00

Opening Ceremony

Annex Hall

18:00 - 19:30

IATDMCT Opening Reception

Monday, September 25

Main Hall

8:40 - 9:30

PL-1

Plenary Lecture 1
Mass spectrometry for research and clinical implementation of TDM&CT
Hans H. Maurer (Saarland University, Germany)

Chair: Koujiro Yamamoto, Japan

9:30 - 10:00

AL-1

Irving Sunshine Award Lecture

Alain Verstraete
Chair: Loralie J. Langman

10:00 - 10:30

Coffee Break

10:30 - 12:00

S-2

TDM for the management of cancer therapy

Chairs: William Clarke, USA / Yuichi Ando, Japan

S-2-1

Benefit of TDM depends on therapeutic class of anticancer drugs
Etienne Chatelut (Institut Universitaire du Cancer de Toulouse, France)

S-2-2

Exposure-response and pharmacogenomics of tyrosine kinase inhibitors
Tomohiro Terada (Shiga University of Medical Science Hospital)

S-2-3

Optimization of CML therapy using TDM
Naoto Takahashi (Akita University, Japan)

13:30 - 14:30

O25-1

General Oral Session

Biomarkers for transplantation

Program No.	Title	Speaker	Institution	Country
O25-1-1	Naturally regulatory T cell-specific demethylated region in FOXP3 as a biomarker to predict acute rejection in kidney transplant patients under immunosuppression with tacrolimus, mycophenolic acid and steroids	Eberhard Wieland	Klinikum Stuttgart	Germany
O25-1-2	Combined Measurement of Immunosuppressive Agents, Creatinine and Hematocrit in a Single Dried Blood Spot Using LC-MSMS and Near-infra-Red Spectrometry	Erik van Maarseveen	University Medical Center Utrecht	The Netherlands
O25-1-3	Biomarkers for steady state concentration prediction of cyclosporine A by pharmacometabolomics and gene polymorphism	Xiao-xue WANG	China-Japan Friendship Hospital	China
O25-1-4	Urinary miR-155-5p and CXCL10 as prognostic and predictive biomarkers of rejection, graft outcome and treatment response in kidney transplantation	OLGA MILLAN	Hospital Clinic of Barcelona, University of Barcelona	Spain

14:30 - 15:00

Coffee Break

15:00 - 17:00

S-3

Biomarkers and TDM of immunosuppressive drugs

S-3-1

Biomarkers in Solid Organ Transplantation: Prospects and Challenges
Eberhard Wieland (Klinikum Stuttgart, Germany)

S-3-2

Clinical implementation of pharmacogenomics in kidney transplantation
Laure Elens (Catholic University of Louvain, Belgium)

S-3-3

Usefulness pharmacogenetic information in liver transplantation
Mercè Brunet (Hospital Clínic of Barcelona, Barcelona University, Spain)

S-3-4

Determinants of intra-graft tacrolimus concentrations in renal transplant recipients
Benedetta Sallustio (The Queen Elizabeth Hospital, Australia)

S-3-5

High intrapatient variability of tacrolimus exposure is associated with poorer outcomes after liver transplantation
Camille Tron (Rennes University Hospital, France)

Room D

10:30 - 12:00

S-4

TDM for multi-drug resistant organisms

S-4-1

Linezolid; why we should question the product information
Deborah Janet Eldrid Marriott (St. Vincent's Hospital, Sydney, Australia)

S-4-2

Colistin: the PK, PD and TD characteristics of this 'old' antibiotic provide the basis for TDM
Roger L. Nation (Monash University, Australia)

S-4-3

Therapeutic drug monitoring of beta-lactam antibiotics
Menino Osbert Cotta (The University of Queensland, Australia)

13:30 - 14:30

O25-2

General Oral Session

CNS and Miscellaneous

Program No.	Title	Speaker	Institution	Country
O25-2-1	CYP2C19 polymorphism affects the efficacy but not drowsiness in the low dose clobazam therapy	Sachiyo Hashi	Kyoto University Hospital	Japan
O25-2-2	Correlation between Serum Concentrations of Clozapine, NDesmethylclozapine and ABCB1 Genotype on Neutrophil Granulocyte Count in Schizophrenia Patients	Robert Lovsletten Smith	Diakonhjemmet Hospital	Norway
O25-2-3	Quantification and explanation of the pharmacokinetic variability in factor VIIIresponse in non-severe hemophilia A patients treated with desmopressin	Reinier van Hest	Academic Medical Center Amsterdam	The Netherlands
O25-2-4	CYP activity in paired human liver and jejunum samples	Veronica Krogstad	University of Oslo	Norway

14:30 - 15:00

Coffee Break

15:00 - 17:00

S-5

IATDMCT-JSTDM YS Joint Symposium 2017

S-5-1

PK and TDM of monoclonal antibodies for inflammatory bowel diseases
Sophie Berends (Academic Medical Center Amsterdam, The Netherlands)

S-5-2

Ultra-sensitive quantification of drugs and endogenous substances in human plasma using UPLC-MS/MS
Yosuke Suzuki (Oita University Hospital, Japan)

S-5-3

Bench-to-bedside research for the dermatological side effects induced by multiple tyrosine kinase inhibitors
Kazuhiro Yamamoto (Kobe University Hospital, Japan)

S-5-4

Therapeutic Drug Monitoring of Antiretrovirals: Applications in Management and Prevention
Mark Marzinke (Johns Hopkins University School of Medicine, USA)

Room E

10:30 - 12:00

S-6

TDM in Asia

S-6-1

TDM in Japan
Toshiyuki Sakaeda (President of JSTDM)

S-6-2

TDM in China
Zhao Rongsheng (Peking University Third Hospital, China)

S-6-3

TDM in India
Smita Pattanaik (Post Graduate Institute of Medical Education and Research, India)

13:30 - 14:30

O25-3

General Oral Session

Drug abuse

Program No.	Title	Speaker	Institution	Country
O25-3-1	Evolution of drug abuse in drivers: a French retrospective analysis of about 9000 cases over a 13-year period	Franck Saint-Marcoux	Limoges University Hospital	France
O25-3-2	Evaluation of an Ion Trap LC-MS/MS insturment (Toxtyper) for drug of abuse screening in oral fluid	Maria Shipkova	Klinikum Stuttgart	Germany
O25-3-3	A new bioassay for detection and activity profiling of synthetic opioids	Christophe Stove	Ghent University	Belgium
O25-3-4	Direct and rapid analysis of drugs in serum by probe electrospray ionization tandem mass spectrometry (PESI/MS/MS)	Tomomi Ohara	Nagoya University	Japan

14:30 - 15:00

Coffee Break

15:00 - 17:00

S-7

Herbal medicines: Toxicity, interactions and interferences in TDM

S-7-1

An overview of herbal remedies and their toxicity
Vanessa Steenkamp (University of Pretoria, South Africa)

S-7-2

The current situation of the assay of herbal medicines
Kiyoyuki Kitaichi (Gifu Pharmaceutical University, Japan)

S-7-3

Clinically important drug-herb interactions
Amitava Dasgupta (University of Texas-Houston Medical School at Houston, USA)

S-7-4

Interferences of herbal medicines in therapeutic drug monitoring
Thomas Y.K. Chan (Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong)

Room C1

10:30 - 11:15

O25-4

General Oral Session

Clinical toxicology (1)

Program No.	Title	Speaker	Institution	Country
O25-4-1	Bisphenol A and its chlorinated derivatives and myocardial infarction in diabetic patients: case-control studies in two European cohorts	Nicolas Venisse	University Hospital of Poitiers	France
O25-4-2	Hydroxychloroquine toxicity: myocardial consequences	Michelle Katsumi Zimmerman	Indiana University	United States of America
O25-4-3	Designer benzodiazepines and opioids: the risk of metabolic interactions	SOULEIMAN EL BALKHI	Limoges University Hospital	France

11:15 - 12:00

O25-5

General Oral Session

Clinical toxicology (2)

Program No.	Title	Speaker	Institution	Country
O25-5-1	Prevalence estimation of pregnant womens alcohol consumption using the new biomarker phosphatidylethanol	Birgit C. P. Koch	Erasmus MC	The Netherlands
O25-5-2	New psychoactive substances produce reactive metabolites - a possible mechanism of toxicity?	Moa Andresen Bergstrom	Sahlgrenska University Hospital	Sweden
O25-5-3	An oxidative reactive metabolite of nevirapine activates inflammasomes leading to nevirapine-induced liver injury	Ryuji Kato	Osaka University of Pharmaceutical Sciences	Japan

13:30 - 14:30

O25-6

General Oral Session

Drug assay

Program No.	Title	Speaker	Institution	Country
O25-6-1	Simultaneous determination of imatinib, sunitinib, erlotinib and metabolites in human plasma by LC-MS/MS	Jennie Ostervall	Karolinska University Laboratory	Sweden
O25-6-2	Simultaneous quantification of busulfan, clofarabine and F-ARA-A using Isotope labelled standards and standard addition in plasma by LC-MS/MS for exposure monitoring in hematopoietic cell transplantation conditioning	Arjen Punt	University Medical Center Utrecht	The Netherlands
O25-6-3	UHPLC-MS/MS based quantification of DOACs and application to patients undergoing cardiac catheterization treated with rivaroxaban	Martin Helge Josef Wiesen	University of Cologne	Germany
O25-6-4	Development and validation of a high performance liquid chromatography tandem mass spectrometric method for the determination of Docetaxel in dried blood spots	Marina Venzon Antunes	Universidade Feevale	Brazil

14:30 - 15:00

Coffee Break

15:00 - 16:00

O25-7

General Oral Session

Infectious diseases

Program No.	Title	Speaker	Institution	Country
O25-7-1	Optimal Vancomycin Dosage in Patients with Heart Failure Based on Population Pharmacokinetics and Monte Carlo Simulation	Yuko Shimamoto	National Cerebral and Cardiovascular Center	Japan
O25-7-2	The novel pharmacokinetic parameter area under the trough level (AUTL) associates the clinical efficacy of vancomycin in elderly patients with methicillin-resistant Staphylococcus aureus pneumonia	Shiro Fukumori	University of Toyama	Japan
O25-7-3	Is the recommended dose of Micafungin suitable for every critically ill patient?	Franck Saint-Marcoux	Limoges University Hospital	France
O25-7-4	Effects of cobicistat on tenofovir durability: is it time to rethink at tenofovir alafenamide trials?	Dario Cattaneo	Luigi Sacco University Hospital	Italy

16:00 - 17:00

O25-8

General Oral Session

Infections in pediatrics

Program No.	Title	Speaker	Institution	Country
O25-8-1	Voriconazole dosing in children under 2 years	Michael Neely	University of Southern California	United States of America
O25-8-2	Population Pharmacokinetics of Amoxicillin and Gentamicin in Term Neonates Undergoing Moderate Hypothermia	Yuma Bijleveld	Academic Medical Center	The Netherlands
O25-8-3	Population pharmacokineticpharmacodynamic modeling and simulation of imipenem for dosing optimization in pediatric patients	Kazuro Ikawa	Hiroshima University	Japan
O25-8-4	Therapeutic Drug Monitoring of Vancomycin in Neonates and Reliability of GFR Estimated by Schwartz Method	Sunwoo Jung	Seoul National University	South Korea

Room Swan

7:30 - 8:30

Roundtable discussion (ticket required)

Annex Hall

Poster & Exhibition

8:00 - 10:00

Poster Pin Up

9:00 - 16:00

Exhibition

10:00 - 12:00

Poster Viewing

10:00 - 10:30

Coffee Break

12:30 - 13:30

P25

Poster Presentation
Lunch will be served.

13:30 - 16:00

Poster Viewing

14:30 - 15:00

Coffee Break

16:00 - 17:00

Poster Removal

17:00 - 18:30

Wine & Cheese Reception (Japanese style)

Tuesday, September 26

Main Hall

8:40 - 9:30

PL-2

Plenary Lecture 2
Why Use TDM and Dashboards for Monoclonal Antibodies?
The Promise of Individualized Therapy
Diane Renee Mould (Projections Research Inc., USA)

9:30 - 10:00

AL-2

C.E. Pippenger Award Lecture

Christoph Hiemke
Chair: Pierre Wallemacq

10:00 - 10:30

Coffee Break

10:30 - 12:00

S-8

Pharmacometric approach on anti-infective medications

S-8-1

Dosing software to optimize antimicrobial therapy based on TDM
Franck Saint-Marcoux (University Hospital of Limoges, France)

S-8-2

Model-based voriconazole dosing in pediatric patients
Michael Noel Neely (Children's Hospital Los Angeles, University of Southern California, USA)

S-8-3

Dose Optimization of Anti-infective Agents - On Earth and in Space
Hartmut Derendorf (University of Florida, USA)

13:00 - 14:30

Annual General Meeting

14:30 - 15:00

Coffee Break

15:00 - 17:00

S-9

Young Scientist Symposium

S-9-1

Model based dosage optimization for pediatric patients
Tomoyuki Mizuno (Cincinnati Children’s Hospital Medical Center, USA)

S-9-2

TDM improves the efficacy of cyclosporine A in aplastic anemia patients
Wangjun Qin (China-Japan Friendship Hospital, China)

S-9-3

Pharmacogenomics in Clinical Practice
Daiki Hira (Ritsumeikan University, Japan)

S-9-4

Re-establishment of target concentrations of immunosuppressive drugs using PKPD modeling
Brenda de Winter (Erasmus Medical Center, the Netherlands)

Room D

10:30 - 12:00

S-10

Progress of TDM for hematopoietic stem cell transplantation

S-10-1

Relevance of TDM to clinical outcomes with busulfan
Jennifer Helen Martin (University of Newcastle, Australia)

S-10-2

Therapeutic drug monitoring(TDM) in paediatric and adult patients on high dose busulfan conditioning therapy: a retrospective analysis including outcomes
Hundie Tesfaye (University Hospital in Motol, Charles University, Czech Republic)

S-10-3

Pharmacokinetic analysis of once-daily intravenous busulfan in combination with fludarabine for elderly AML/MDS patients
Shingo Yamazaki (Chiba University Hospital, Japan)

S-10-4

Improved busulfan exposure in HCT: evaluating a decade of TDM experience in children and adults
Erik van Maarseveen (University Medical Center Utrecht, The Netherlands)

S-10-5

Pharmacokinetically-guided dosing of melphalan in children undergoing hematopoietic stem cell transplantation: A test dose approach using sparse optimal sampling
Kana Mizuno (Cincinnati Children's Hospital Medical Center, United States of America)

13:30 - 14:30

Japanese Session (presented in Japanese language)

14:30 - 15:00

Coffee Break

15:00 - 17:00

S-11

Drug exposure during pregnancy and lactation

S-11-1

Trends in drug use during pregnancy; what can happen to the neonate?
Birgit C.P. Koch (Erasmus MC, The Netherlands)

S-11-2

Biological specimens and approaches to testing designed to identify drug-exposed newborns
Gwendolyn Appell McMillin (University of Utah and ARUP Laboratories, USA)

S-11-3

Neonatal drug exposure via lactation
Shinya Ito (The Hospital for Sick Children, University of Toronto, Canada)

S-11-4

Use of iPS cells for the study of placental drug transport
Kenji Ikeda (Osaka Ohtani University, Japan)

Room E

10:30 - 12:00

S-12

TDM for central nervous system drugs

S-12-1

TDM for a new class of anti-epileptic drugs
Ikuko Yano (Kobe University Hospital, Japan)

S-12-2

Validation of a High-Throughput Method for the Quantitation of Pregabalin in Plasma Using Ultra-fast SPE-MS/MS.
Loralie J. Langman (Mayo Clinic, United States of America)

S-12-3

Lamotrigine and valproate drug interactions — the role of pharmacogenomics
Iva Klarica Domjanovic (Agency for Medicinal Products and Medical Devices, Croatia)

S-12-4

Drug monitoring and dose individualisation of anti-epileptic drugs: a role for pharmacometrics
Sven Christiaan van Dijkman (Leiden Academic Centre for Drug Research, The Netherlands)

S-12-5

Neonatal PBPK modeling of morphine disposition with OCT1 transporter developmental expression
Chie Emoto (Cincinnati Children's Hospital Medical Center, United States of America)

14:30 - 15:00

Coffee Break

15:00 - 17:00

S-13

Debate session: Generics

S-13-1

What are the issues?
Teun van Gelder (Erasmus Medical Center Rotterdam, The Netherlands)

S-13-2

The most different generics of tacrolimus are bioequivalent to each other and brand in kidney and liver transplant patients: A randomized, controlled trialf
Uwe Christians (University of Colorado, USA)

S-13-3

Evaluating transplant donor and recipient pharmacogenetics and its Impact on tacrolimus and metabolite pharmacokinetics in bioequivalence studies
Alexander Andhony Vinks (Cincinnati Children’s Hospital Medical Center, USA)

S-13-4

Generic immunosuppression in kidney transplantation; Japanese perspectives
Yoshihiko Watarai (Nagoya Daini Red Cross Hospital, Japan)

Room C1

10:30 - 11:15

O26-1

General Oral Session

Immunosuppressive drugs: assey and genotyping

Program No.	Title	Speaker	Institution	Country
O26-1-1	Assessment of Automated Electrochemiluminescence Immunoassay for Everolimus	Kimitaka Suetsugu	Kyushu University Hospital	Japan
O26-1-2	Long-term performance of laboratory developed LC-MS/MS tests and an FDAapproved immunoassay for the therapeutic drug monitoring of Everolimus	Bjoern Schniedewind	University of Colorado	United States of America
O26-1-3	Is CYP3A5*3 genotyping for Tacrolimus dosing really beneficial?	Tester F. Ashavaid	P.D. Hinduja National Hospital and Medical Research Centre	India

11:15 - 12:00

O26-2

General Oral Session

Immunosuppressive drugs: clinical practice

Program No.	Title	Speaker	Institution	Country
O26-2-1	Is the whole blood TDM of immunosuppressors the best way to manage treatment of pediatric patients undergoing liver transplantation?	Antonio D'Avolio	University of Turin and Amedeo di Savoia Hospital	Italy
O26-2-2	A comparison of dosage, blood, kidney and hepatic tissue Tacrolimus concentrations in transplant recipients and the influence of the concentrations and dosage on efficiency of treatment in immunosuppressive therapy	Tomasz Pawinski	Medical University of Warsaw	Poland
O26-2-3	Survival analysis to the occurrence of adverse events in pediatric liver transplant patients	Natalia Riva	Hospital de Pediatria JP Garrahan	Argentina

14:30 - 15:00

Coffee Break

15:00 - 16:00

O26-3

General Oral Session

Pharmacogenomics (1)

Program No.	Title	Speaker	Institution	Country
O26-3-1	Tacrolimus updated guidelines through Population-based Pharmacokinetics modeling: How to benefit more from CYP3A pre-emptive genotyping prior to kidney transplantation	Laure Elens	Universite catholique de Louvain	Belgium
O26-3-2	Pharmacogenetic profiling of CYP2D6 in Western Indian population	Tester F. Ashavaid	Hinduja National Hospital & Medical Research Center	India
O26-3-3	DPYD polymorphisms and fluoropyrimidine toxicity — a single institution case control study	Nada Bozina	University of Zagreb	Croatia
O26-3-4	Dihydropyrimidine dehydrogenase deficiency in patients treated with 5FU or capecitabine based regimens: a tertiary care centre experience	Pavithran Keechilat	Amrita Insitute of Medical sciences	India

16:00 - 17:00

O26-4

General Oral Session

Pharmacogenomics (2)

Program No.	Title	Speaker	Institution	Country
O26-4-1	Small-dosing clinical study: pharmacokinetic, pharmacogenomic (SLCO2B1 and ABCG2), and interaction (atorvastatin and grapefruit Juice) profiles of five probes for OATP2B1 and BCRP	Yushi Kashihara	Kyushu University	Japan
O26-4-2	Isoniazid-induced hepatotoxicity:implication of N-acetyl transferase 2 and CYP2E1	Karim Aouam	University of Monastir	Tunisia
O26-4-3	Genetic polymorphisms of CYP2B6, CYP2C19, CYP2D6 and CYP3A4 genes and methadone therapy	Nurfadhlina Musa	Universiti Sains Malaysia	Malaysia
O26-4-4	Impact of cytochrome P450 2C19 polymorphisms on the pharmacokinetics of tacrolimus when coadministered with voriconazole	Chiyo K. Imamura	Keio University	Japan

Room Swan

7:30 - 8:30

Roundtable discussion (ticket required)

Annex Hall

Poster & Exhibition

9:00 - 10:00

Poster Pin Up

9:00 - 17:00

Exhibition

10:00 - 10:30

Coffee Break

10:00 - 12:00

Poster Viewing

12:30 - 13:30

P26

Poster Presentation
Lunch will be served.

13:30 - 16:00

Poster Viewing

14:30 - 15:00

Coffee Break

16:00 - 17:00

Poster Removal

Grand Prince Hotel Kyoto Prince Hall (B2F)

19:00 - 23:00

Congress Dinner and Party

Wednesday, September 27

Main Hall

8:40 - 9:30

PL-3

Plenary Lecture 3
Circulating cell-free DNA as a new tool for personalized pharmacotherapy
Michael Oellerich (University Medical Center Göttingen (UMG), Germany)

9:30 - 10:00

AL-3

Victor Armstrong Young Investigator Award Lecture

Markus Meyer
Chair: Teun van Gelder

10:00 - 10:30

Coffee Break

10:30 - 12:00

S-14

Dried blood spot analysis: Are we ready for implementation?

S-14-1

Analytical perspective on developing a DBS assay for daily routine
Sara Capiau (Ghent University, Belgium)

S-14-2

Clinical perspective on developing a DBS assay for daily routine
Christophe Stove (Ghent University, Belgium)

S-14-3

Development of a liquid chromatography tandem mass spectrometric method for quantification of mycophenolic acid and its glucuronides in dried blood spot samples
Hiroaki Yamaguchi (Tohoku University Hospital, Japan)

S-14-4

Guardians experience of collecting dried blood spots from children with epilepsy-preliminary results from a survey
Camilla Hanna Linder (Karolinska University Laboratory and Karolinska Institutet, Sweden)

13:30 - 13:45

AL-4

Patsalos Prize Lecture

Michael Neely
Chair: Loralie J. Langman

13:45 - 15:30

S-15

Applying TDM to HIV and TB therapy

S-15-1

Role of TDM in anti-retroviral therapy
Dario Cattaneo (Unit of Clinical Pharmacology– Luigi Sacco University Hospital, Italy)

S-15-2

Optimal HIV medications in pediatric patients
Natella Yurievna Rakhmanina (Children’s National/George Washington University, USA)

S-15-3

TDM of Anti-Tuberculosis Medications
Charles Arthur Peloquin (University of Florida, USA)

S-15-4

Therapeutic Drug Monitoring of Rifampicin & Isoniazid and implications of acetylator genotype on plasma levels
Prerna Kulbhushan Chawla (P.D. Hinduja National Hospital and Medical Research Centre, India)

15:30 - 16:00

Coffee Break

16:00 - 17:00

Closing Ceremony

Room D

10:30 - 12:00

S-16

TDM of 5-FU

S-16-1

Management of 5-Fluorouracil Treatment using Therapeutic Drug Monitoring (TDM)
Edward Chu (University of Pittsburgh Cancer Institute, USA)

S-16-2

Study on the relationship among gene polymorphism, 5-FU plasma concentration and adverse reactions in the chemotherapy of colorectal cancer
Lu Chen (Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, China)

S-16-3

Therapeutic drug monitoring of 5-fluorouracil by LC-MS/MS
Anna Hansson (Karolinska University Laboratory, Sweden)

S-16-4

Determination of endogenous concentrations of uracil and dihydrouracil em dried saliva spots by LC-MS/MS: a new tool to access dihydropyrimidine dehydrogenase deficiency
Marina Antunes (Universidade Feevale, Brazil)

S-16-5

Pharmacokinetically guided 5-fluorouracil dose adjustment versus body-surface-area dosing in advanced pancreatic cancer patients: real world data
Azucena Aldaz (Clínica Universidad de Navarra, Spain)>

13:30 - 15:30

S-17

Assay and screening for drugs in clinical and forensic toxicology

S-17-1

Comprehensive Toxicology Screening in Clinical and Post Mortem Toxicology
Eric J.F. Franssen (OLVG Hospital, The Netherlands)

S-17-2

Alternative matrices for detection of drugs of abuse
Marilyn A. Huestis (NMS Labs, Inc., USA)

S-17-3

Advances of mass spectrometry for targeted and untargeted drug screening
Kara L. Lynch (UCSF, San Francisco, USA)

S-17-4

Cutting-edge mass spectrometric screening methods for new psychoactive substances
Kei Zaitsu (Nagoya University Graduate School of Medicine, Japan)

15:30 - 16:00

Coffee Break

Room E

10:30 - 12:00

S-18

TDM for cardiovascular and endocrine diseases

S-18-1 

TDM of cardiovascular drugs
Tsuyoshi Shiga (Tokyo Women's Medical University, Japan)

S-18-2

Role of TDM and psychological profile assessment in treatment-resistant hypertensive patients
Pierre Wallemacq (Cliniques universitaires St Luc, Belgium)

S-18-3

DEVELOPMENT OF A DRIED BLOOD SPOT (DBS) BASED MEASUREMENT OF EIGHT ANTIHYPERTENSIVE DRUGS AND FOUR ACTIVE METABOLITES TO ASSESS TREATMENT ADHERENCE
Jorie Versmissen (Erasmus MC, The Netherlands)

S-18-4

Reappraisal of TDM in Pharmacogenomic Generation
Hirotoshi Echizen (Meiji Pharmaceutical University, Japan)

13:30 - 15:30

S-19

Assessing human exposure to environmental pollutants

S-19-1

Introduction: A new Scientific Committee on Environmental Health and Toxicology at IATDMCT.
Scope and goals
Nicolas Venisse (Centre Hospitalier Universitaire de Poitiers, France)

S-19-2

Distribution of Pharmaceuticals in Clinical Wastewater from Medical Institutions and Development of Advanced Water Treatment Systems
Takashi Azuma (Graduate School of Pharmaceutical Sciences, Osaka University of Pharmaceutical Science, Japan)

S-19-3

Optimising human biomonitoring targets for environmental contaminants based on in vitro metabolism results- a case study of flame retardants
Nele Van den Eede (University of Antwerp/Ziekenhuis Netwerk Antwerpen, Belgium)

S-19-4

Physiologically based pharmacokinetic modeling as tool for the interpretation of biomonitoring data in the exposure assessment of environmental contaminants
Sami Haddad (Université de Montréal, Canada)

15:30 - 16:00

Coffee Break

Room C1

10:30 - 11:15

O27-1

General Oral Session

Pharmacometrics (1)

Program No.	Title	Speaker	Institution	Country
O27-1-1	New population pharmacokinetic model that predicts the individual starting dose of tacrolimus following pediatric renal transplantation	Louise M. Andrews	Erasmus MC	The Netherlands
O27-1-2	Hospital pharmacometrics contributing to the treatment of connective tissue diseases with low dose cyclosporine A	Chika Ogami	University of Toyama	Japan
O27-1-3	When covariates and inter-occasion variability do not necessarily improve the performances of population pharmacokinetic (popPK) models used for therapeutic drug monitoring: the case of micafungin	Jean-Baptiste Woillard	CHU Limoges, Univ Limoges	France

11:15 - 12:00

O27-2

General Oral Session

Pharmacometrics (2)

Program No.	Title	Speaker	Institution	Country
O27-2-1	Multiple-model optimization of sparse sample phenotyping of drug disposition utilizing population modeling	Ida Robertsen	University of Oslo	Norway
O27-2-2	Mechanistic pharmacodynamic analysis on safety profiles of eribulin in patients with breast cancer using data obtained by post-marketing observational study	Takahisa Kawamura	Shizuoka Cancer Center	Japan
O27-2-3	Model-informed precision dosing of sirolimus in children with vascular anomalies: Pharmacokinetic-guided dose adjustment and design of ageappropriate starting dosing regimens	Tomoyuki Mizuno	Cincinnati Children's Hospital Medical Center	United States of America

13:30 - 14:30

O27-3

General Oral Session

Oncology (1)

Program No.	Title	Speaker	Institution	Country
O27-3-1	Towards therapeutic drug monitoring of everolimus in oncology? Results of an exploratory study	Jean-Baptiste Woillard	CHU Limoges, Univ Limoges	France
O27-3-2	Development of an S-1 dosage formula based on renal function by a prospective pharmacokinetic study	Eisuke Booka	Keio University	Japan
O27-3-3	Towards in-silico-guided within-cycle adjustment of high-dose methotrexate in patients with lymphoid malignancies	Sebastian G. Wicha	University of Hamburg	Germany
O27-3-4	Effect of proton pump inhibitors coadministration on the plasma concentration of erlotinib in patients with non-small cell lung cancer (2nd report)	Masahiro Ogami	Ibaraki Prefectural Central Hospital and Sciences, University of Tsukuba	Japan

14:30 - 15:30

O27-4

General Oral Session

Oncology (2)

Program No.	Title	Speaker	Institution	Country
O27-4-1	Therapeutic drug monitoring (TDM) approaches for the treatment of neonates and children with cancer: a UK experience	Gareth James Veal	Newcastle University	United Kingdom
O27-4-2	Population pharmacokinetic modeling of alemtuzumab in pediatric patients undergoing allogeneic hematopoietic cell transplantation for non-malignant diseases	Tsuyoshi Fukuda	Cincinnati Children's Hospital Medical Center	United States of America
O27-4-3	The Effects of Advanced Age and Serum alpha1-Acid Glycoprotein on Docetaxel Unbound Exposure and Dose-limiting Toxicity in Cancer Patients	Hirotsugu Kenmotsu	Shizuoka Cancer Center	Japan
O27-4-4	UGT1A1 polymorphism may be a prognostic indicator of stage I ovarian clear cell carcinoma patients treated with irinotecan	Tomoko Yoshihama	Keio University	Japan

15:30 - 16:00

Coffee Break

Room Swan

7:30 - 8:30

Roundtable discussion (ticket required)

Annex Hall

Poster & Exhibition

9:00 - 10:00

Poster Pin Up

9:00 - 15:30

Exhibition

10:00 - 12:00

Poster Viewing

10:00 - 10:30

Coffee Break

12:30 - 13:30

P27

Poster Presentation
Lunch will be served.

13:30 - 15:30

Poster Viewing

15:30 - 16:00

Coffee Break

15:30 - 16:00

Poster Removal

Thursday, September 28

Post Congress Symposium
“Guidelines and Consensus Documents for TDM”

Room D

8:40 - 8:45

Opening Remark
Yusuke Tanigawara (Chair of the 15th IATDMCT Congress, Keio University, Japan)

8:45 - 9:15

PC-1

Consensus Document on TDM of Everolimus
Maria Shipkova (Immunosuppressive Drugs Scientific Committee of the IATDMCT,
Klinikum Stuttgart, Zentralinstitut für Klinische Chemie und Laboratoriumsmedizin,, Germany)

9:15 - 9:45

PC-2

Guidelines on Therapeutic Drug Monitoring of Immunosuppressive Drugs
Used in Organ Transplantation
Satohiro Masuda (Japanese Society of Therapeutic Drug Monitoring (JSTDM),
Kyushu University Hospital, Japan)

9:45 - 10:15

PC-3

Analytical methods of Measurement for Immunosuppressive Drug Concentrations
Pawel K. Kunicki (Immunosuppressive Drugs Scientific Committee of the IATDMCT, Institute of Cardiology, Poland)

10:15 - 10:45

Break

10:45 - 11:15

PC-4

Dried blood spot (DBS) sampling and analysis guideline
Christophe Stove (Alternative Sampling Strategies Committee of the IATDMCT
Laboratory of Toxicology, Ghent University, Belgium)

11:15 - 11:45

PC-5

Guidelines for Therapeutic Drug Monitoring of Cardiovascular Drugs
Tsuyoshi Shiga (Japanese Society of Therapeutic Drug Monitoring (JSTDM),
Tokyo Women's Medical University, Japan)

11:45 - 13:00

Lunch

13:00 - 13:30

PC-6

Therapeutic Drug Monitoring of 5-Fluorouracil: An Approach Whose Time Has Come
Edward Chu (TDM in Oncology Scientific Committee of the IATDMCT,
University of Pittsburgh Cancer Institute, USA)

13:30 - 14:00

PC-7

Busulfan TDM: Current consensus and discrepancy
Erik van Maarseveen (TDM in Oncology Scientific Committee of the IATDMCT,
University Medical Center Utrecht, The Netherlands)

14:00 - 14:30

PC-8

Guidelines for Therapeutic Drug Monitoring of Imatinib
William Alex Clarke (TDM in Oncology Scientific Committee of the IATDMCT,
Johns Hopkins University School of Medicine, USA)

14:30 - 15:00

Break

15:00 - 15:30

PC-9

Draft guidance for linezolid TDM
Gauri G. Rao (Anti-Infective Drugs Committee of the IATDMCT, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, USA)

15:30 - 16:00

PC-10

Guidelines for Therapeutic Drug Monitoring of Antiepileptic Drugs
Toshiaki Sendo (Japanese Society of Therapeutic Drug Monitoring (JSTDM),
Okayama University Hospital, Japan)

16:00 - 16:15

Closing Remark
Satohiro Masuda
(Secretary of the 15th IATDMCT Congress, Kyushu University Hospital, Japan)